ANNX

Over the past six months (April 2026 - October 2026), Annexon's stock was influenced by several events. In August 2026, the company reported a wider-than-expected net loss for Q2, missing analyst estimates and causing a 6.37% stock drop. September saw routine inducement grants, an announcement of presenting patient baseline characteristics from its Vonaprument Phase 3 ARCHER II trial, a significant share purchase by the CEO, and a bullish analyst thesis. Investor sentiment built towards key Q4 2026 catalysts, causing a stock surge in late September. However, in October, shares declined 12.61% due to broader market weakness, including a bond market selloff and rising Treasury yields impacting small-cap biotech. Q4 2026 is expected to bring key readouts from the ARCHER II trial, though its timeline was extended.